Semi-chronic increase in striatal level of 3,4-dihydroxyphenylacetaldehyde does not result in alteration of nigrostriatal dopaminergic neurones
| Autor: | H. Legros, J.-J. Bonnet, Jean Costentin, Nathalie Dourmap, François Janin |
|---|---|
| Přispěvatelé: | Unité de neuropsychopharmacologie expérimentale, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS), Endothélium microcirculatoire cérébral et lésions du système nerveux central au cours du développement (Néovasc), Normandie Université (NU)-Normandie Université (NU)-Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Neuropsycho-pharmacologie expérimentale |
| Rok vydání: | 2004 |
| Předmět: |
Male
L‐dopa Levodopa Time Factors Monoamine oxidase Dopamine [SDV]Life Sciences [q-bio] Dopamine Agents Aldehyde dehydrogenase brain aldehyde dehydrogenase 4‐dihydroxyphenylacetaldehyde 3 4-Dihydroxyphenylacetaldehyde Pharmacology Rats Sprague-Dawley 03 medical and health sciences Cellular and Molecular Neuroscience chemistry.chemical_compound 0302 clinical medicine Disulfiram medicine Animals Enzyme Inhibitors Chromatography High Pressure Liquid 030304 developmental biology Neurons 0303 health sciences biology Chemistry Dopaminergic Aldehyde Dehydrogenase Corpus Striatum 3. Good health rats Vesicular monoamine transporter in vivo biology.protein 3 4-Dihydroxyphenylacetic Acid 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Journal of Neuroscience Research Journal of Neuroscience Research, Wiley, 2004, 75 (3), pp.429-435. ⟨10.1002/jnr.10880⟩ |
| ISSN: | 1097-4547 0360-4012 |
| Popis: | International audience; This work was carried out to evaluate the potential in vivo toxicity of 3,4‐dihydroxyphenylacetaldehyde (DOPAL), an aldehyde formed from dopamine by monoamine oxidase (MAO) that is oxidised mainly to 3,4‐dihydroxyphenylacetic acid (DOPAC) by brain aldehyde dehydrogenases (ALDH). In this study, male Sprague‐Dawley rats were treated with levodopa (L‐dopa)‐benserazide, which increases DOPAL production by MAO, and disulfiram, an irreversible inhibitor of ALDH, which reduces the formation of DOPAC from DOPAL. An acute systemic intraperitoneal (i.p.) injection of 100 mg/kg disulfiram and L‐dopa‐benserazide (100 mg/kg + 25 mg/kg, 24 hr later) significantly increased DOPAL striatal level. A 30‐day treatment with disulfiram (100 mg/kg i.p., once every 2 days) and L‐dopa‐benserazide (100 mg/kg + 25 mg/kg, two times/day) did not affect either indexes used to assess integrity of the nigrostriatal dopaminergic neurones (i.e., the striatal content in dopamine and binding to the vesicular monoamine transporter on striatal membranes). These results do not evidence any deleterious effect of DOPAL and argue against toxicity of L‐dopa therapy |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text